(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 November 2017 (23.11.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/198347 A1

(51) International Patent Classification:
A61K 31/00 (2006.01) *A61K 31/5386* (2006.01)
A61K 31/5377 (2006.01) *A61P 17/02* (2006.01)

(21) International Application Number:
PCT/EP2017/025137

(22) International Filing Date:
17 May 2017 (17.05.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/338,111 18 May 2016 (18.05.2016) US
17151843.4 17 January 2017 (17.01.2017) EP

(71) Applicants: **PIQUR THERAPEUTICS AG** [CH/CH]; Hochbergerstrasse 60c, 4057 Basel (CH). **THE TRUSTEES OF THE UNIVERSITY OF PENNESYLVANIA** [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104 (US).


(72) Inventors: **FABBRO, Doriano**; Im Lee 54, 4144 Arleshiem (CH). **HEBEISEN, Paul**; St. Albanring 184, 4052 Basel (CH). **HILLMANN-WUELLNER, Petra**; Dorfstrasse 49b, 8102 Oberengstringen (CH). **STUETZ, Anton**; Teichweg 4, 4813 Altmünster (CH). **SEYKORA, John, T.**; 202 Laurel Lane, Broomall, PA 19008 (US). **BEAUFILS, Florent**; 28 rue des ecureuils, 68870 Bartenheim (FR).

(74) Agent: **SPERRLE, Martin**; Austrasse 24, 4051 Basel (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: TREATMENT OF SKIN LESIONS



(I)



(II)



(57) Abstract: The present invention is relates to a compound of formula (I), wherein X^1, X^2 and X^3 are, independently of each other, N or CH; with the proviso that at least two of X^1 X^2 and X^3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X^1, X^2 and X^3 are N; R^1 and R^2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R^3 and R^4 are independently of each other H, C_1-C_3alkyl optionally substituted with one or two OH, C_1-C_2fluoroalkyl, C_1-C_2alkoxy, C1alkoxyC_1-C_3alkyl, CN, or C(O)O-C_1-C_2alkyl; or R^3 and R^4 form together a bivalent residue -R^5R^6- selected from C_1-C_3alkylene optionally substituted with 1 to 4 F, -CH_2-O-CH_2-, -CH_2-NH-CH_2-, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R^7; wherein R^7 is independently at each occurrence C_1-C_3alkyl optionally substituted with one or two OH, C_1-C_2fluoroalkyl, C_1-C_2alkoxyC_1-C_3alkyl, C_3-C_6cycloalkyl; or two R^7 substituents form together a bivalent residue-R^8R^9- selected from Ci-C3alkylene optionally substituted with 1 to 4 F, -CH_2-O-CH_2- or -O-CH_2CH_2-O-; with the proviso that at least one of R^1 and ^{R2}is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in the prevention or treatment of a skin lesion in a subject.

[Continued on next page]

WO 2017/198347 A1

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*